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Abstract: BACKGROUND: Valve thrombosis has yet to be fully evaluated after transcatheter aortic
valve implantation. This study aimed to report the prevalence, timing, and treatment of transcatheter
heart valve (THV) thrombosis. METHODS AND RESULTS: THV thrombosis was defined as follows
(1) THV dysfunction secondary to thrombosis diagnosed based on response to anticoagulation therapy,
imaging modality or histopathology findings, or (2) mobile mass detected on THV suspicious of thrombus,
irrespective of dysfunction and in absence of infection. Between January 2008 and September 2013,
26 (0.61%) THV thromboses were reported out of 4266 patients undergoing transcatheter aortic valve
implantation in 12 centers. Of the 26 cases detected, 20 were detected in the Edwards Sapien/Sapien XT
cohort and 6 in the Medtronic CoreValve cohort. In patients diagnosed with THV thrombosis, the median
time to THV thrombosis post-transcatheter aortic valve implantation was 181 days (interquartile range,
45-313). The most common clinical presentation was exertional dyspnea (n=17; 65%), whereas 8 (31%)
patients had no worsening symptoms. Echocardiographic findings included a markedly elevated mean
aortic valve pressure gradient (40.5±14.0 mm Hg), presence of thickened leaflets or thrombotic apposition
of leaflets in 20 (77%) and a thrombotic mass on the leaflets in the remaining 6 (23%) patients. In 23
(88%) patients, anticoagulation resulted in a significant decrease of the aortic valve pressure gradient
within 2 months. CONCLUSIONS: THV thrombosis is a rare phenomenon that was detected within
the first 2 years after transcatheter aortic valve implantation and usually presented with dyspnea and
increased gradients. Anticoagulation seems to have been effective and should be considered even in
patients without visible thrombus on echocardiography.
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1Transcatheter aortic valve implantation (TAVI) has emerged as an alternative to surgical aortic valve replacement (AVR) 
in high operative risk or inoperable patients.1,2 Given its mini-
mally invasive nature and acceptable clinical outcomes, TAVI 
has recently become an established and popular treatment option 
for high-risk groups with severe aortic stenosis.3–5 However, 
because of their rare occurrence, the incidence and characteristics 
of several causes of prosthetic valve dysfunction, such as valve 
thrombosis, pannus formation, calcification, endocarditis, etc, 
have yet to be reported in the literature. Of these, valve thrombo-
sis is of particular interest as the optimal antithrombotic therapy 
after TAVI remains controversial. Even in the context of surgical 
Background—Valve thrombosis has yet to be fully evaluated after transcatheter aortic valve implantation. This study aimed 
to report the prevalence, timing, and treatment of transcatheter heart valve (THV) thrombosis.
Methods and Results—THV thrombosis was defined as follows (1) THV dysfunction secondary to thrombosis diagnosed 
based on response to anticoagulation therapy, imaging modality or histopathology findings, or (2) mobile mass detected 
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AVR using bioprosthetic valves, the optimal antithrombotic ther-
apy remains an area of debate.6,7 The reported incidences of valve 
thrombosis postsurgical AVR using bioprostheses ranges widely 
from as low as 0.03% to 5.0%.8–12 Conversely, data on transcathe-
ter heart valve (THV) thrombosis are scarce and restricted to sev-
eral case reports and small case series.13–15 A recent meta-analysis 
on clinical outcomes after TAVI using Valve Academic Research 
Consortium definitions reported a 1.2% pooled estimated inci-
dence of THV thrombosis.16,17 However, this figure was based on 
only 2 previous articles studying a small number of patients (0% 
in 305 patients and 2.7% in 130 patients).18,19 Furthermore, to the 
best of our knowledge, there are no descriptive articles reporting 
not only the incidence but also details about THV thrombosis. 
The aim of this study was to evaluate the prevalence, timing, 
characteristics, and optimal treatment of THV thrombosis.
Methods
Of 4266 consecutive patients who underwent TAVI with Edwards 
Sapien/Sapien XT or Medronic CoreValve between January 2008 
and September 2013 in 12 centers, 26 patients diagnosed with THV 
were retrospectively analyzed. A standardized case report form was 
used by all participating centers; data were collected by retrospective 
review of hospital records by the site investigators and after quality 
controls were sent to the coordinating center. These data were col-
lected as part of a formal ongoing registry. Follow-up was performed 
by outpatient visits or phone calls. Each participating center obtained 
institutional review board or ethics committee approval according to 
local standards. Informed consent was obtained from each patient ac-
cording to institutional standard practice. Antiplatelet and antithrom-
botic regimes after TAVI were dependent on each hospital’s protocol.
Definitions
THV dysfunction was defined as (1) mean aortic valve pressure 
gradient (AVPG) ≥20 mm Hg or aortic valve area <1.2 cm2 or peak 
velocity ≥3 m/s, or (2) moderate or more prosthetic valve regurgita-
tion, which was not recorded post procedure. THV thrombosis was 
defined as follows: (1) THV dysfunction secondary to thrombosis 
diagnosed based on response to anticoagulation therapy, imaging 
modality (echo or computed tomography), or histopathology find-
ings, or (2) mobile mass detected on THV suspicious of thrombus, 
irrespective of dysfunction, and in the absence of infection. Cases 
were excluded if other main potential causes for THV dysfunction 
were suspected (excluding possible THV thrombosis) based on im-
aging modality or histopathology findings: stent creep; pannus; cal-
cification; support structure deformation, underexpansion or trauma; 
mal-sizing; endocarditis; native leaflet prolapse impeding prosthetic 
leaflet motion; malposition; acute mal-coaptation; leaflet wear, tear/
perforation, prolapse, or retraction; suture breakage or disruption.16 
Cases with clinical signs (sepsis, fever, embolic, or immunologic 
phenomena), biochemistry (C-reactive protein, erythrocyte sedimen-
tation rate, white blood cell count), or microbiology (blood cultures) 
consistent with underlying endocarditis were excluded.
Statistical Analysis
The values were presented as mean±SD or median (interquartile 
range) for normally and not normally distributed continuous vari-
ables, respectively, or as counts and percentages for categorical 
variables. Changes in AVPG (at the time of THV thrombosis and af-
ter anticoagulation) were calculated and analyzed using the paired 
Student t test. The proportion of patients with AVPG <20 mm Hg at 
the time of diagnosis of THV thrombosis and after anticoagulation 
were analyzed using McNemar test. Detailed follow-up was avail-
able only for patients who were diagnosed with THV thrombosis. All 
the analyses are retrospective and were performed using SPSS for 
Windows, version 19.0 (IBM SPSS Inc, Chicago, IL).
Results
Baseline clinical characteristics are shown in Table 1. As far 
as conditions potentially associated with thrombotic events 
are concerned, the incidence of previous stroke (19%), atrial 
fibrillation (19%), and history of cancer (12%) was not higher 
as compared with historical data.20–22 Furthermore, mean left 
ventricular ejection fraction was 59.1±12.1% and only 2 
patients (8%) had left ventricular ejection fraction <35%.
Procedural characteristics are shown in Table 2. Valve-in-
valve (ie, TAVI in a degenerated aortic prosthesis) procedures 
were performed in 3 (12%) patients. According to operators’ 
judgment, valve positioning was appropriate in 24 (92%) 
patients, whereas low implantation occurred in 2 (8%) patients. 
About echo findings, postprocedural mean AVPG <20 mm Hg 
was recorded in almost all cases (n=25; 96%), whereas only 1 
patient had a slightly higher gradient (23 mm Hg).
Prevalence, Timing, Clinical Presentation, and Echo 
Findings of THV Thrombosis
Details of THV thrombosis are shown in Table 3. All the cases of 
THV thrombosis were detected within 2 years after TAVI (median 
time to THV thrombosis: 181 [interquartile range, 45–313] days; 
range, 3–735 days). As shown in Figure 1, only 1 patient had 
discontinued antiplatelet treatment at the time of diagnosis of 
THV thrombosis. No significant differences in antiplatelet/anti-
thrombotic regimes were observed in patients with acute (within 
1 month) and late (after 1 month) THV thrombosis (Table I in 
the Data Supplement). The majority of patients (n=17/26; 65%) 
presented with worsening dyspnea, whereas in 31% of the patients 
THV thrombosis was not associated with worsening symptoms 
and was detected on routine follow-up echocardiography. A 
WHAT IS KNOWN
•	The reported incidence of valve thrombosis postsur-
gical bioprosthetic aortic valve replacement ranges 
from as low as 0.03% to 5.0%, but data on transcath-
eter heart valve (THV) thrombosis are limited.
WHAT THE STUDY ADDS
•	THV thrombosis occurred in 0.61% of TAVI patients 
in a large multicentre registry, with the majority of 
patients presenting with worsening dyspnea and in-
creased THV gradient.
•	All THV thrombosis cases occurred within 2 years 
from transcatheter aortic valve implantation and 
were not associated with discontinuation of anti-
platelet/antithrombotic therapy or with an underly-
ing thrombogenic diathesis.
•	Thrombosis should be suspected in cases of prema-
ture THV dysfunction, even if a thrombotic mass is 
not clearly detected.
•	Anticoagulation resulted in restoration of normal 
THV function within 2 months of treatment, and 
should be considered the treatment of choice when 
THV thrombosis is suspected.
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transesophageal echo was performed in the majority of the cases 
(20/26), providing detailed anatomic and functional information. 
None of the patients had neurological events or other evidence of 
thromboembolic phenomena. Overall, mean AVPG was signifi-
cantly increased (40.5±14.0 mm Hg) and was >20 mm Hg in 92% 
(n=24). Of the 2 patients without increased AVPG, 1 had severe 
AR (postprocedural AR: mild) with thickened leaflets detected on 
echo and the other had a mobile mass suggestive of thrombus, 
despite already being on warfarin with optimal international nor-
malized ratio levels (2.0–3.0). The most common morphological 
presentation of thrombus on echocardiography was thickened 
leaflets or thrombotic apposition of leaflets (n=20; 77%), whereas 
only in a minority of cases a thrombotic mass was seen on the 
leaflets (n=6; 23%). THV thromboses characterized by throm-
botic mass tended to occur earlier post-TAVI compared with 
thromboses because of thickened leaflets or thrombotic apposition 
(Table II in the Data Supplement). Neither echocardiography nor 
computed tomography showed geometric deformation or disloca-
tion of the implanted THV or evidence of thrombus on the frame.
Treatment and Clinical Outcomes for THV 
Thrombosis
Of the 26 patients with THV thrombosis, 23 (88%) patients 
were treated with medical therapy, such as oral vitamin K 
antagonists with/without bridging heparin (unfractionated hep-
arin or low-molecular–weight heparin; n=21); heparin without 
subsequent oral vitamin K antagonists because of high bleed-
ing risk or patient refusal (n=2). Anticoagulation was effective 
and resulted in significant decrease of the AVPG (Figure 2) or 
disappearance of the thrombotic mass in all 23 patients (mean 
AVPG at the time of THV thrombosis, 41.9±12.3 and after 
anticoagulation, 16.9±6.4 mm Hg; patient number with AVPG 
<20 mm Hg: 1/23 and 17/23, at the time of THV thrombosis 
diagnosis and after anticoagulation, respectively; P<0.001). 
Two patients (8%) underwent percutaneous valve-in-valve, and 
1 (4%) surgical AVR at the discretion of the operators or phy-
sicians.23 In both these patients, a trial of anticoagulation was 
not attempted, as THV thrombosis was not initially suspected.
Examples are shown in Figures 3–5: (1) a case with serial 
echo findings showing acute resolution of thrombus within 4 
days after initiation of anticoagulation therapy for a 29-mm 
Edwards Sapien XT thrombosis (Figure 3), (2) a case with 
serial computed tomographic findings of a 29-mm Medtronic 
CoreValve thrombosis suggesting a beneficial effect of anti-
coagulation in a case of persistent THV thrombosis that had 
been diagnosed 1 year before and had only partially responded 
to dual antiplatelet therapy (Figure 4), and (3) pictures of an 
explanted valve and its histopathology from a patient who 
Table 1. Baseline Clinical Characteristics of Patients With 
Transcatheter Heart Valve Thrombosis
n=26
Age, y 79.7±6.9
Sex, male 14 (53.8)
BMI, kg/m2 27.1±4.4
Logistic EuroSCORE 17.8±14.4
STS PROM score 5.6±4.1
Diabetes mellitus 3 (11.5)
Hypertension 21 (80.8)
Dyslipidemia 15 (57.7)
Smoking history 2 (7.7)
Chronic renal failure (eGFR <60 mL/min per 1.73 m2) 8 (30.8)
Chronic liver disease 1 (3.8)
Chronic obstructive pulmonary disease 9 (34.6)
Peripheral arterial disease 5 (19.2)
Coronary artery disease (detected at last angiography 
just before TAVI)
8 (30.8)
Previous MI 3 (11.5)
Previous PCI 3 (11.5)
Previous CABG 7 (26.9)
Previous valve surgery 3 (11.5)
Previous stroke 5 (19.2)
Previous pulmonary embolism 1 (3.8)
Porcelain aorta 1 (3.8)
Atrial fibrillation 5 (19.2)
History of cancer* 3 (11.5)
Echo findings before TAVI
  LVEF, % 59.1±12.1
  LVEF <35% 2 (7.7)
  Aortic valve area, mm2 0.71±0.24
  Mean aortic valve gradient, mm Hg 50.7±19.4
  Maximal aortic valve gradient, mm Hg 83.6±29.3
  More than moderate AR 4 (15.4)
Values are mean±SD or n (%). AR indicates aortic regurgitation; BMI, body 
mass index; CABG, coronary artery bypass grafting; eGFR, estimated glomerular 
filtration rate; EuroSCORE, European system for cardiac operative risk 
evaluation; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, 
percutaneous coronary intervention; STS PROM, society of thoracic surgeons 
predicted risk of mortality; and TAVI, trancatheter aortic valve implantation.
*Of all the 3 patients, cancers had been already cured at the time of TAVI.
Table 2. Procedural Characteristics
n=26
Edwards Sapien or Sapien XT* 20 (76.9)
  23 mm 6 (23.1)
  26 mm 13 (50)
  29 mm 1 (3.8)
Medtronic CoreValve 6 (23.1)
  26 mm 2 (7.7)
  29 mm 4 (15.4)
Valve-in-valve 3 (11.5)
Postdilatation 4 (15.4)
Appropriate valve positioning 24 (92.3)
Echo findings after TAVI
  Mean aortic valve gradient, mm Hg 11.3±4.5
  Mean aortic valve gradient <20 mm Hg† 25 (96.2)
  Maximal aortic valve gradient, mm Hg 22.7±8.6
  Moderate AR 2 (7.7)
  Severe AR 0 (0)
Values are mean±SD or n (%). AR indicates aortic regurgitation; and TAVI, 
transcatheter aortic valve implantation.
*Sapien in 3 cases; Sapien XT in 17 cases.
†Only 1 patient had 23 mm Hg of mean aortic valve gradient at post procedure.
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underwent surgical AVR for Medtronic CoreValve thrombosis 
(Figure 5).23
Three patients diagnosed with THV thrombosis died. Two 
patients died, despite being effectively treated with anticoagu-
lation: 1 because of pneumonia and 1 because of acute heart 
failure (left ventricular ejection fraction: 30%). One patient 
died because of recurrent valve thrombosis at 3 months after 
percutaneous valve-in-valve implantation. In the remaining 23 
patients, no embolic events originating from thrombi attached 
to THV leaflets were reported, after initiation of anticoagula-
tion therapy, which was recommended indefinitely.
Discussion
The main findings from this are:
1. The prevalence of THV thrombosis was low (0.61%), however, 
this figure should be interpreted with caution as it probably 
underestimates the true prevalence.
2. All cases of THV thrombosis were detected within 2 years 
from TAVI and were not associated with discontinuation of an-
tiplatelet/antithrombotic therapy, or a thrombogenic diathesis 
(as indicated by presence of previous stroke, atrial fibrillation, 
low left ventricular ejection fraction, and history of cancer).
3. Majority of patients presented with worsening dyspnea (65%) 
and increased THV gradient (92%).
4. Anticoagulation resulted in restoration of normal THV func-
tion within 2 months of treatment and should be considered 
the treatment of choice once THV thrombosis is suspected 
(thickened leaflets or apposition of leaflets) even without evi-
dence of an obvious thrombotic mass on the valve leaflets.
Prevalence and Timing of THV Thrombosis
To the best of our knowledge, this is the first study reporting 
details about THV thrombosis. In our study, the prevalence of 
THV thrombosis was 0.61%. A previous meta-analysis showed 
a pooled estimated rate of THV thrombosis of 1.2%; however, 
this was based on only 2 small studies (0% of 305 patients and 
2.7% of 130 patients).6,18,19 In the context of surgical AVR, there 
is a wide range in the reported incidences of valve thrombosis 
from as low as 0.03% to 5.0%.8–12 These reported incidences 
concur with the one from our study, despite the fact that TAVI 
patients have more comorbidities predisposing them to pro-
thrombotic states. This suggests that the bioprosthetic material 
inserted in the aortic valve position rather than other predispos-
ing factors, plays the major role in valve thrombosis. Further-
more, our data showed that all THV thrombosis cases occurred 
within 2 years after TAVI (the overwhelming majority of cases 
occurred within 1 year) suggesting that biological processes, 
such as fibrin deposits and platelet aggregation on foreign 
Figure 1. Details of antithrombotic therapy post procedure and at 
the time of diagnosis of transcatheter heart valve (THV) thrombo-
sis. IQR indicates interquartile range; PT-INR, prothrombin time–
international normalized ratio; and TAVI, transcatheter aortic valve 
implantation.
Figure 2. Significant decrease in mean aortic valve pressure 
gradient after treatment with anticoagulation. IQR indicates inter-
quartile range; TAVI, transcatheter aortic valve implantation; and 
THV, transcatheter heart valve.
Table 3. Details of THV Thrombosis
n=26
Median time to THV thrombosis, d 181 (IQR, 45–313; range, 3–735)
Incidence of THV thrombosis 26/4266 (0.61)
  Edwards Sapien or Sapien XT 20/2813 (0.71)
  Medtronic CoreValve 6/1453 (0.41)
Clinical presentation
  Dyspnea 17 (65.4)
  No worsened symptoms 8 (30.8)
  NSTEMI, acute heart failure 1 (3.8)
Echo findings at THV thrombosis
  LVEF, % 58.0±10.6
  Mean aortic valve gradient, mm Hg 40.5±14.0
  Mean aortic valve gradient <20 mm Hg* 2 (7.7)
  Maximal aortic valve gradient, mm Hg 65.1±19.0
  Worsened AR (to more than moderate) 
as compared with post procedure
2 (7.7)
Thrombus morphology
  Thickened leaflets or thrombotic 
apposition of leaflets
20 (76.9)
  Thrombotic mass on leaflets 6 (23.1)
Values are mean±SD or n (%). AR indicates aortic regurgitation; IQR, 
interquartile range; LVEF, left ventricular ejection fraction; NSTEMI, non–ST-
segment–elevation myocardial infarction; and THV, transcatheter heart valve.
*Of the 2 patients without increased aortic valve gradient, one had severe 
AR (postprocedural AR: mild) with thickened leaflets detected by echo, and 
the other one had a mobile thrombotic mass, despite already taking warfarin 
(prothrombin time–international normalized ratio, 2.0–3.0).
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surfaces (endothelium devoid valve leaflets), occurring in the 
early period after TAVI, may predispose to valve thrombosis.
Clinical Presentation
Surprisingly, 31% of patients did not present with worsening 
symptoms at the time of diagnosis of THV thrombosis, highlight-
ing the importance of follow-up echocardiography. This high rate 
of subclinical THV thrombosis could be explained by the fact that 
patients who have undergone TAVI have been preconditioned to 
the severe accompanying symptoms of severe aortic stenosis, 
hence slight changes in breathlessness may go unnoticed. It is 
therefore recommended, that regardless of symptomatic status, 
all patients with TAVI should undergo regular routine follow-up.
Potential Causes for THV Thrombosis
Our data suggest that THV thrombosis may occur without 
specific underlying circumstances. However, there are several 
predisposing factors, which should be discussed.
(1) Small valve size leading to patient–prosthesis mismatch 
is generally considered to be associated with unfavorable out-
comes24,25 and THV underexpansion is one of the possible trig-
gers for THV thrombosis. However, the fact that 77% of THV 
thrombosis cases in this study occurred in patients who received 
THV >26 mm with acceptable postprocedural AVPG suggests 
that small size or underexpanded valves are unlikely to have 
contributed to THV thrombosis. (2) Even though no consensus 
exists on optimal antiplatelet/antithrombotic therapy after TAVI 
implantation, it is commonly accepted that premature cessation 
of antiplatelet/antithrombotic therapy may lead to thrombotic 
events. However, in our study, all but 1 patient were on some 
kind of antiplatelet or antithrombotic agent at the time of THV 
thrombosis diagnosis, suggesting that THV thrombosis can 
occur, despite patients’ drug compliance. (3) Even though the 
study was not designed to compare THV thrombosis rates in 
patients with different types of THV, the fact that THV throm-
bosis prevalence was comparable between the 2 widely used 
THV: 0.71% with Sapien/Sapien XT; 0.41% with Medtronic 
CoreValve, may suggest that thrombosis can occur irrespective 
of implanted valve type with similar mechanisms of thrombo-
sis (Table III in the Data Supplement). (4) Aggressive postdi-
lation has also been considered one of the potential risks for 
valve leaflet damage with subsequent higher thrombosis risks. 
However, in our study, only 15% of THV thrombosis cases had 
undergone postdilatation after valve implantation. (5) Another 
possible cause of THV thrombosis is geometric deformation of 
the aortic valve stent, which may predispose to thrombus for-
mation as a result of flow turbulence.26 However, once again 
this was not evident in our study. (6) We cannot exclude the 
possibility of underlying inherited thrombophilias among 
THV thrombosis patients, such as antiphospholipid antibody 
Figure 3. Serial transesophageal echo images showing acute 
resolution of thrombus 4 days after initiation of anticoagulation. 
At 8 months after implantation of a 29-mm Edwards Sapien 
XT, mean aortic valve pressure gradient (AVPG) increased as 
compared with the one recorded post procedure (from 10 to 
47 mm Hg), despite ongoing dual antiplatelet therapy. A and B, 
Transesophageal echocardiography showing thickened leaflets 
suggesting mural thrombosis of all 3 leaflets without evident 
valve calcification and valve dislocation. C and D, Transesopha-
geal echocardiography after 4 days of anticoagulation showing 
all the 3 leaflets thinner with significantly decreased mean AVPG 
(from 47 to 17 mm Hg). THV indicates transcatheter heart valve.
Figure 4. Serial computed tomographic (CT) images 
showing the effect of oral anticoagulation on chronic 
valve thrombosis. At 17 months after implanta-
tion of a 29-mm Medtronic CoreValve, mean aortic 
valve pressure gradient (AVPG) assessed by echo, 
increased as compared with that reported at 5 
months (from 10 to 50 mm Hg), despite ongoing 
aspirin. This patient was treated with dual antiplate-
let therapy (DAPT) until 32 months (mean AVPG was 
still 32 mm Hg), then switched to anticoagulation. 
A, Transesophageal echocardiography showing 
thrombotic mass on the aortic side of prothetic 
leaflets at 23 months after transcatheter aortic valve 
implantation (TAVI; at that time still on DAPT). B–D, 
CT showing suspected low-density thrombi on the 
aortic side of the aortic valve cusps, without evident 
valve calcification or valve dislocation at 23 months 
after TAVI (at the time still on DAPT). B′–D′, Follow-
up CT images showing thrombi disappearance after 
8 months of anticoagulation (from 32 to 40 months 
after TAVI) therapy, and associated significantly 
decreased mean AVPG (8 mm Hg) on echo.
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syndrome, antithrombin III, protein C, or S deficiency or Factor 
V Leiden, which were not investigated in this study. However, 
when taking into account the absence of previous thromboem-
bolic events, an underlying thrombophilia is less likely to have 
been the contributing factor to THV thrombosis.
Optimal Treatment for Valve Thrombosis
The most commonly used treatment regimen for THV thrombosis 
was anticoagulation, which proved to be extremely efficacious. 
Anticoagulation was effective even for chronic and organized 
thrombi (Figure 4). This highlights the importance of antico-
agulation as soon as valve thrombosis is suspected, not only in 
cases with visible thrombotic mass on valve leaflets but also in 
cases with THV dysfunction associated with thickened leaflets or 
apposition of leaflets with increased AVPG on echocardiography.
Current Guidelines on Antiplatelet/Antithrombotic 
Agents After TAVI
Although the bioprosthetic valves used in open heart sur-
gery and TAVI are different and patients treated with TAVI 
are more fragile as compared with those who undergo sur-
gical AVR, there are some inconclusive historical data on 
antiplatelet/antithrombotic agents after bioprosthetic surgical 
AVR. After TAVI, current guidelines from American Heart 
Association/American College of Cardiology/Society of Tho-
racic Surgeons recommend that (1) aspirin should be used 
indefinitely, (2) concomitant clopidogrel for 3 to 6 months, 
and (3) if vitamin K antagonists is indicated, no concomitant 
clopidogrel.6 Furthermore, European Society of Cardiology 
guidelines recommend (1) aspirin or clopidogrel indefinitely, 
(2) combination of aspirin and clopidogrel early after TAVI, 
and (3) if vitamin K antagonists is indicated no antiplatelet 
therapy.27,28 The main justification for use of antiplatelet and 
antithrombotic treatments post-TAVI is the prevention of isch-
emic events, mainly cerebrovascular ones. However, the low 
THV thrombosis incidence rates and the risks of anticoagula-
tion-related bleeding7 may not allow recommendation of rou-
tine use of anticoagulants after TAVI, not unless concomitant 
diseases, such as atrial fibrillation, mechanical mitral valve 
replacement, or previous thromboembolic events are present.
Limitations
First, the lack of data on the entire TAVI population followed in 
this registry did not allow us to estimate the cumulative risk of 
Figure 5. Images demonstrating valve thrombosis on cusps of aortic side. At 12 months after implantation of a 26-mm Medtronic CoreV-
alve, mean aortic valve pressure gradient increased as compared with that observed immediately post procedure (from 8 to 41 mm Hg), in a 
patient on ongoing aspirin. A, Transesophageal echocardiography showing thickened leaflets with restricted motion (aortic valve area 0.69 
cm2). B–D, Computed tomography showing hypo-dense thickened leaflets without change in prosthesis position or significant deformation 
of the stent by any calcification. E, The in situ visual inspection of the implant revealed a normal seating of the CoreValve with a translucent 
neointimal sheath covering the upper portion of the nitinol frame. The free edges of the valve leaflets were thin, and no calcifications were 
noted. The leaflets were almost immobile because of the presence of a brown-colored thrombotic host tissue covering exclusively the aortic 
side. F and G, Glistening white fibrous-like tissue covered the fabric skirt of the inflow portion of the device on outer and inner surfaces and 
formed a ridge of pannus extending into the inflow orifice and partially onto the ventricular surface of the valve cusps. H, aortic-side surfaces 
and I, ventricular-side surfaces. Specimens of each valve leaflet fixed with formalin. Fragments of friable pink-tan to brown-tan mural throm-
bus covered the aortic surfaces of the valve cusps. J, The valve leaflets showed intact pericardial collagen with few scattered chronic inflam-
matory cells. There was focal mild neointimal growth on the ventricular surfaces of leaflets and adherent bland fibrin and platelet thrombus on 
the aortic surfaces. There was no calcification on Vonkossa stain. A–G and J, were reproduced from Lancellotti et al23 with permission of the 
publisher. Copyright ©2013, American Heart Association, Inc.
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THV thrombosis as a time-related outcome, or to evaluate risk 
factors for thrombosis. Given the retrospective nature of the 
study, attrition and selection bias are inherent limitations. In par-
ticular, deceased patients with sudden, unknown, or uncertain 
cause of death may have died secondary to undiagnosed THV 
thrombosis; hence our data may be underestimating the true 
prevalence. Furthermore, the discussion points about potential 
causes of THV thrombosis should only be viewed as speculative. 
Future large multicenter prospective studies are needed to con-
firm the prevalence reported in this current study and to identify 
potential predictors of THV thrombosis in the TAVI population. 
Another limitation of this study is the absence of data on inherited 
thrombophilias, even though the absence of previous thrombotic 
events among patients with THV thrombosis discourages, yet 
cannot exclude, a potential association with inherited thrombo-
philias. Moreover, platelet function tests were not undertaken in 
this study, therefore, it is not possible to assess whether patients 
with thrombosis were nonresponders to the antiplatelet regimes. 
A future, large, multicenter prospective randomized controlled 
study with stringent echocardiographic follow-up monitoring is 
required to clarify whether a specific antiplatelet regime post-
TAVI would reduce the risk of THV thrombosis.
Conclusions
THV thrombosis is a rare phenomenon that was detected 
within the first 2 years after TAVI and usually presented with 
dyspnea and increased gradients. Anticoagulation seems to 
have been effective and should be considered even in patients 
without visible thrombus on echocardiography.
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SUPPLEMENTAL MATERIAL 
Suppl. Table 1 
 Acute thrombosis 
(within 1 month) 
(n=3) 
Late thrombosis (after 
1 month) (n=23) 
P value 
Edwards Sapien 3 (100) 17 (73.9) 0.313 
Valve-in-valve 1 (33) 2 (8.7) 0.209 
Anti-thrombotic therapy at the 
time of THV thrombosis 
  0.943 
DAPT  2 (67) 10 (43.5)  
SAPT 1 (33) 10 (43.5)  
Aspirin plus warfarin 0 1 (4.3)  
Clopidogrel plus dabigatran 0 1 (4.3)  
None 0 1 (4.3)  
Symptomatic 2 (67) 16 (70.0) 0.919 
DAPT = dual antiplatelet therapy, SAPT = single antiplatelet therapy, THV = transcatheter heart 
valve  
 
Suppl. Table 2 
 Thickened leaflets or 
thrombotic apposition of 
leaflets (n=20) 
Thrombotic mass on 
leaflets (n=6) 
P values 
Time from TAVI (days) 248±200 115±105 0.132 
Post-TAVI AVPG 11.6±4.9 10.3±3.5 0.575 
Median AVPG at the time of 
THV thrombosis diagnosis 
41.9±13.6 35.8±15.5 0.366 
AVPG = aortic valve pressure gradient, TAVI = transcatheter aortic valve implantation, THV = 
transcatheter heart valve  
 
 
 
 
 
 
 
 
Suppl. Table 3 
 
Edwards Sapien (n = 
20) 
Medtronic CoreValve (n 
= 6) 
P value 
Time to THV 
thrombosis, days 
215 ± 194 226 ± 193 0.906 
Clinical 
presentation  
 0.245 
Dyspnea/NSTEMI, 
acute heart failure 
15 (75.0) 3 (50.0)  
No worsened 
symptoms 
5 (25.0) 3 (50.0)  
Echo findings at 
THV thrombosis 
   
LVEF, % 56.1 ± 10.6 64.0 ± 9.1 0.115 
Mean aortic valve 
gradient, mm Hg 
40.4 ± 15.7 40.7 ± 6.8 0.968 
Maximal aortic 
valve gradient, mm 
Hg 
64.5 ± 21.1 67.0 ± 11.8 0.786 
Worsened AR (to 
more than moderate) 
as compared to 
post-procedure 
1 (5.0) 1 (16.7) 0.347 
Thrombus 
morphology 
  0.671 
Thickened leaflets or 
thrombotic apposition 
of leaflets 
15 (75.0) 5 (83.3)  
Thrombotic mass on 
leaflets 
5 (25.0) 1 (16.7)  
AR = aortic regurgitation, LVEF = left ventricular ejection fraction, NSTEMI = non-ST-elevation 
myocardial infarction, THV = transcatheter heart valve. 
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